UBS Group AG Buys 1,513,893 Shares of Omeros Corporation $OMER

UBS Group AG boosted its stake in Omeros Corporation (NASDAQ:OMER) by 213.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,222,982 shares of the biopharmaceutical company’s stock after purchasing an additional 1,513,893 shares during the quarter. UBS Group AG’s holdings in Omeros were worth $38,180,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in OMER. B. Riley Wealth Advisors Inc. bought a new position in Omeros in the 2nd quarter worth about $32,000. Sei Investments Co. bought a new position in Omeros in the 2nd quarter worth about $40,000. Tower Research Capital LLC TRC boosted its stake in Omeros by 829.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 11,971 shares during the period. Russell Investments Group Ltd. boosted its stake in Omeros by 113.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 5,677 shares during the period. Finally, BNP Paribas Financial Markets boosted its stake in Omeros by 548.7% in the 2nd quarter. BNP Paribas Financial Markets now owns 25,272 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 21,376 shares during the period. Institutional investors own 48.79% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on OMER shares. HC Wainwright lifted their price target on Omeros from $20.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. D. Boral Capital reiterated a “buy” rating and set a $36.00 price target on shares of Omeros in a research report on Tuesday, April 21st. Zacks Research upgraded Omeros from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Omeros in a research report on Tuesday, April 21st. Finally, Wall Street Zen downgraded Omeros from a “buy” rating to a “hold” rating in a research report on Sunday, April 26th. Two investment analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Omeros presently has an average rating of “Moderate Buy” and an average price target of $40.33.

Omeros Trading Down 1.3%

Shares of NASDAQ OMER opened at $14.64 on Friday. The stock has a market cap of $1.06 billion, a price-to-earnings ratio of -29.28 and a beta of 2.66. Omeros Corporation has a 1-year low of $2.95 and a 1-year high of $17.65. The stock’s 50-day moving average is $12.00 and its 200 day moving average is $11.17.

Omeros (NASDAQ:OMER) last announced its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported $3.14 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $3.69. On average, analysts forecast that Omeros Corporation will post -1.54 EPS for the current fiscal year.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.